Supplemental Table 1. Unadjusted weighted means and percentages (standard errors) ${ }^{1}$. All persons ages 20 years and older by serum 25hydroxyvitamin D concentration (nmol/L). NHANES III baseline survey 1988-94 with follow-up through 2006.

| Variables | Serum total 25-hydroxyvitamin D (nmol/L) |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $<20$ | 20-29 | 30-39 | 40-49 | 50-59 | 60-74 | 75-99 | 100-119 | $\geq 120$ |
| Age (yr) at Interview | 46 (1.9) | 46 (0.9) | 47 (0.7) | 47 (0.7) | 47 (0.7) | 45 (0.5) | 43 (0.7) | 41 (1.0) | 37 (0.8) |
| Person-Years Follow-up (yr) | 13.0 (0.4) | 13 (0.3) | 13 (.2) | 14 (0.2) | 14 (0.2) | 14 (0.2) | 14 (0.3) | 14 (0.3) | 14 (0.4) |
| Serum 25(OH)D (nmol/L) ${ }^{3}$ | 17 (0.2) | 26 (0.1) | 35 (0.1) | 45 (0.1) | 55 (0.1) | 67 (0.1) | 85 (0.2) | 108 (0.3) | 139 (1.4) |
| Calculated Glomerular Filtration Rate $\mathrm{mL} /\left(\min ^{*} 1.73 \mathrm{~m}^{2}\right)^{4}$ | 99 (2.3) | 100 (1.3) | 95 (1.2) | 92 (0.9) | 92 (0.7) | 91 (0.6) | 90 (0.8) | 91 (0.9) | 92 (1.5) |
| Body Mass Index ( $\mathrm{kg} / \mathrm{m}^{2}$ ) | 27.2 (0.6) | 28.2 (0.4) | 28.1 (0.2) | 27.7 (0.3) | 27.0 (0.2) | 26.3 (0.2) | 25.4 (0.2) | 24.6 (0.2) | 24.1 (0.4) |
| Systolic Blood Pressure (mm Hg) | 129 (2.0) | 124 (1.1) | 125 (0.7) | 125 (0.6) | 123 (0.7) | 122 (0.5) | 121 (0.7) | 120 (1.1) | 119 (1.1) |
| Men (\%) | 29 (4.5) | 31 (1.7) | 35 (1.7) | 43 (1.7) | 48 (1.3) | 52 (1.3) | 58 (1.2) | 55 (2.6) | 52 (3.6) |
| Mexican-Americans (\%) | 5 (1.4) | 7 (0.7) | 7 (0.8) | 7 (0.7) | 6 (0.6) | 5 (0.4) | 3 (0.3) | 2 (0.3) | 1 (0.4) |
| non-Hispanic blacks (\%) | 48 (6.2) | 44 (2.4) | 27 (1.7) | 15 (1.0) | 8 (0.8) | 4 (0.4) | 2 (0.3) | 1 (0.2) | 1 (0.4) |
| non-Hispanic whites (\%) | 40 (6.7) | 38 (2.6) | 53 (2.9) | 66 (1.9) | 78 (1.6) | 84 (1.2) | 91 (1.0) | 94 (1.2) | 97 (0.7) |
| Other Race/Ethnic Group (\%) | 6 (3.3) | 11 (2.5) | 13 (1.6) | 11(1.3) | 8 (1.1) | 7 (1.1) | 4 (0.9) | 3 (1.2) | 1 (0.5) |
| Season (\% Winter) | 73 (5.5) | 57 (5.4) | 51 (4.8) | 47 (4.4) | 38 (4.4) | 36 (3.6) | 29 (3.9) | 23 (3.4) | 19 (4.8) |
| Current Smokers - Yes (\%) | 39 (4.9) | 34 (2.9) | 31 (1.6) | 27 (1.5) | 27 (1.7) | 25 (1.2) | 28 (1.8) | 34 (3.3) | 33 (5.0) |
| Leisure Time Physical Activity |  |  |  |  |  |  |  |  |  |
| Low < 4.65 METS/week | 65 (6.1) | 62 (2.2) | 53 (2.3) | 49 (1.8) | 39 (1.8) | 35 (1.7) | 28 (1.5) | 26 (3.0) | 20 (2.8) |
| Moderate 4.65-22.5 METS/week | 23 (6.0) | 22 (1.8) | 28 (1.5) | 29 (1.5) | 34 (1.7) | 37 (1.3) | 36 (1.7) | 35 (3.1) | 31 (3.6) |


| High > 22.5 METS/Week | 12 (2.2) | 16 (1.5) | 20 (1.9) | 22 (1.3) | 27 (1.3) | 27 (1.7) | 36 (1.9) | 39 (3.3) | 49 (4.4) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Education: < High School (\%) | 26 (3.9) | 29 (1.7) | 28 (1.7) | 27 (1.6) | 26 (1.3) | 25 (1.3) | 21 (1.9) | 21 (2.9) | 20 (3.8) |
| Education: High School (\%) | 37 (4.1) | 38 (2.4) | 37 (1.7) | 33 (1.5) | 33 (1.2) | 31 (1.1) | 34 (1.4) | 36 (2.9) | 26 (3.5) |
| Education: > High School (\%) | 37 (4.8) | 33 (2.5) | 35 (1.8) | 40 (2.0) | 41 (1.4) | 44 (1.6) | 44 (2.5) | 43 (3.8) | 54 (4.9) |
| Medicine Usage ${ }^{5}$ - Yes (\%) | 20 (5.9) | 16 (1.6) | 16 (1.3) | 16 (1.2) | 17 (1.0) | 14 (0.9) | 13 (1.0) | 19 (2.4) | 24 (3.4) |
| Self-reported History of : |  |  |  |  |  |  |  |  |  |
| Diabetes (\%) | 6 (1.7) | 6 (0.8) | 10 (0.9) | 6 (0.7) | 6 (0.7) | 5 (0.5) | 3 (0.3) | 3 (1.1) | 2 (1.3) |
| Congestive Heart Failure (\%) | 4 (1.6) | 2 (0.5) | 3 (0.5) | 2 (0.5) | 3 (0.4) | 2 (0.3) | 2 (0.3) | 1 (0.4) | 1 (0.5) |
| Stroke (\%) | 3 (1.8) | 3 (0.8) | 3 (0.6) | 2 (0.4) | 2 (0.3) | 2 (0.3) | 2 (0.2) | 2.1 (0.8) | 0 (0.2) |
| Heart Attack (\%) | 4 (1.7) | 2 (0.6) | 4 (0.6) | 4 (0.6) | 4 (0.6) | 4 (0.5) | 3 (0.4) | 2 (0.8) | 2 (0.9) |
| Cancer ${ }^{6}$ (\%) | 6 (1.6) | 3 (0.6) | 3 (0.7) | 5 (0.6) | 4 (0.7) | 4 (0.4) | 4 (0.5) | 4 (1.2) | 2 (1.2) |

Sources: Centers for Disease Control and Prevention, National Center for Health Statistics, Third National Health and Nutrition Examination Survey, 1988-1994 and the public use version of the NHANES III Linked Mortality File.

Sources: Centers for Disease Control and Prevention, National Center for Health Statistics, Third National Health and Nutrition Examination Survey, 1988-1994 and the public use version of the NHANES III Linked Mortality File.
${ }^{1}$ Standard error in parentheses.
${ }^{2}$ The t-test for the difference between those assumed alive and assumed deceased is significant with $\mathrm{p}<0.01$.
${ }^{3}$ Based on serum 25(OH)D values ( $\mathrm{nmol} / \mathrm{L}$ ) calibrated to the DiaSorin assay kit available in 2004 using the following equation: NHANES III $25(\mathrm{OH}) \mathrm{D}_{\text {Corrected to } 2004 \text { RIA }}=0.8429$ x NHANES III 25(OH)D ${ }_{1988-94 \text { RIA }}+2.5762(\mathrm{mmol} / \mathrm{L})$. [See Looker et al., AJCN 2008;88:1519-1527 for more details.]
${ }^{4}$ Serum creatinine ( $\mathrm{mg} / \mathrm{dL}$ ) was calibrated to the Cleveland Clinic Research Laboratory (CCRL) using the equation CCRL creatinine $=0.96$ (NHANES III creatinine value) - $0.184 \mathrm{mg} / \mathrm{dL}$ (Please see Selvin et al. Am J Kidney Dis 2007;50:918-926) and glomerular filtration rate (GFR)
was calculated using the IDMS-Traceable Modification of Diet in Renal Disease (MDRD) Study equation (Please see Levy et al. Ann Intern Med 2006;145:247-254 for more details.)
${ }^{5}$ Self-reported usage any of the following prescription medications: anticonvulsants, glucocorticoids, estrogens, loop diuretics or thiazide diuretics during the 30 days prior to interview.
${ }^{6}$ Self-reported history of cancer other than skin cancer.

Supplemental Table 2. Unweighted raw numbers of deaths ( $\mathrm{N}_{\text {Deaths }}$ ) by length of follow-up, demographic group, cause of death and by baseline serum concentration of total 25-hydroxyvitamin D (nmol/L). NHANES III baseline 1988-1994.

| Category | Total | $<20$ | 20-29 | Serum total 25-hydroxyvitamin D (nmol/L) |  |  |  |  | 100-119 | $\geq 120$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | 30-39 | 40-49 | 50-59 | 60-74 | 75-99 |  |  |
| Follow-up |  |  |  |  |  |  |  |  |  |  |
| Follow-up to 2000 (9 years) | 2,257 | 47 | 191 | 381 | 409 | 385 | 439 | 319 | 69 | 17 |
| Follow-up to 2006 (15 years) | 3,784 | 79 | 297 | 592 | 694 | 668 | 775 | 533 | 110 | 36 |
| Demographic Group ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Sex ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Men | 2,066 | 28 | 113 | 265 | 360 | 375 | 480 | 351 | 66 | 28 |
| Women | 1,718 | 51 | 184 | 327 | 334 | 293 | 295 | 182 | 44 | 8 |
| Age (yr) at interview ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| 20-64 | 1,167 | 33 | 120 | 217 | 230 | 173 | 214 | 133 | 30 | 17 |
| 65+ | 2,617 | 46 | 177 | 375 | 464 | 495 | 561 | 400 | 80 | 19 |
| Race/Ethnicity ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Mexican-American | 687 | 15 | 67 | 125 | 170 | 109 | 113 | 73 | 9 | 6 |
| non-Hispanic black | 878 | 40 | 137 | 221 | 175 | 125 | 111 | 56 | 10 | 3 |
| non-Hispanic white | 2,134 | 22 | 89 | 230 | 335 | 417 | 535 | 392 | 87 | 27 |
| Other ${ }^{2}$ | 85 | 2 | 4 | 16 | 14 | 17 | 16 | 12 | 4 | . |
| Causes of Death ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Cancer | 826 | 9 | 58 | 129 | 151 | 150 | 172 | 119 | 25 | 13 |
| Cardiovascular Diseases | 1,660 | 33 | 131 | 274 | 311 | 278 | 338 | 238 | 49 | 8 |
| Other | 1,106 | 31 | 90 | 165 | 201 | 206 | 220 | 150 | 31 | 12 |
| Accidents | 145 | 4 | 13 | 19 | 24 | 27 | 31 | 20 | 5 | 2 |
| Unknown | 47 | 2 | 5 | 5 | 7 | 7 | 14 | 6 | . | 1 |

Sources: Centers for Disease Control and Prevention, National Center for Health Statistics, Third National Health and Nutrition Examination Survey, 1988-1994 and the public use version of the NHANES III Linked Mortality File.
${ }^{1}$ Follow-up through 2006 (15 years).
${ }^{2}$ Due to small sample size, no data analyses were conducted for the "Other" group.

Supplemental Table 3. Unweighted raw sample size (N) by length of follow-up, demographic group, cause of death and by baseline serum concentration of total 25-hydroxyvitamin D (nmol/L). NHANES III baseline 1988-1994.

| Category | Total | Serum total 25-hydroxyvitamin D ( $\mathrm{nmol} / \mathrm{L}$ ) |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $<20$ | 20-29 | 30-39 | 40-49 | 50-59 | 60-74 | 75-99 | 100-119 | $\geq 120$ |
| Follow-up |  |  |  |  |  |  |  |  |  |  |
| Follow-up to 2000 (9 years) | 15,099 | 251 | 1,270 | 2,340 | 2,790 | 2,526 | 3,046 | 2,156 | 518 | 202 |
| Follow-up to 2006 (15 years) | 15,099 | 251 | 1,270 | 2,340 | 2,790 | 2,526 | 3,046 | 2,156 | 518 | 202 |
| Demographic Group ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Sex ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Men | 7,216 | 68 | 394 | 896 | 1,243 | 1,285 | 1,680 | 1,260 | 285 | 105 |
| Women | 7,883 | 183 | 876 | 1,444 | 1,574 | 1,241 | 1,366 | 896 | 233 | 97 |
| Age (yr) at interview ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| 20-64 | 11,359 | 200 | 1,034 | 1,831 | 2,104 | 1,826 | 2,233 | 1,562 | 397 | 172 |
| 65+ | 3,740 | 51 | 236 | 509 | 686 | 700 | 813 | 594 | 121 | 30 |
| Race/Ethnicity ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Mexican-American | 4,088 | 46 | 305 | 660 | 907 | 763 | 859 | 452 | 73 | 23 |
| non-Hispanic black | 4,052 | 164 | 754 | 1,067 | 879 | 536 | 419 | 197 | 25 | 11 |
| non-Hispanic white | 6,352 | 36 | 173 | 513 | 865 | 1,124 | 1,633 | 1,440 | 402 | 166 |
| Other ${ }^{2}$ | 607 | 5 | 38 | 100 | 139 | 103 | 135 | 67 | 18 | 2 |
| Causes of Death ${ }^{1}$ |  |  |  |  |  |  |  |  |  |  |
| Denominator | 15,099 | 251 | 1,270 | 2,340 | 2,790 | 2,526 | 3,046 | 2,156 | 518 | 202 |

Sources: Centers for Disease Control and Prevention, National Center for Health Statistics, Third National Health and Nutrition Examination Survey, 1988-1994 and the public use version of the NHANES III Linked Mortality File.
${ }^{1}$ Follow-up through 2006 (15 years)
${ }^{2}$ Due to small sample size, no data analyses were conducted for the "Other" group.

## Materials and Methods

Measurements. Serum 25(OH)D measurements in NHANES III were performed by the National Center for Environmental Health, CDC by using a radioimmunoassay (RIA) kit (DiaSorin, Stillwater, MN) $(9,10)$. The manufacturer reformulated the kit in the late 1990s by introducing an antibody that improved binding. In a subsequent calibration study of 150 banked serum samples an equation to estimate NHANES III values using the more recent kit was developed (11). The equation is:

NHANES III $25(\mathrm{OH}) \mathrm{D}_{\text {Reformulated } 2004 \text { RIA }}=$
[0.8429 x NHANES III 25(OH)D $\left.{ }_{1988-94 ~ R I A}\right]+2.5762 \mathrm{nmol} / \mathrm{L}$

Reformulated values for serum $25(\mathrm{OH}) \mathrm{D}$ in $\mathrm{nmol} / \mathrm{L}(\mathrm{ng} / \mathrm{ml} \approx \mathrm{nmol} / \mathrm{L} / 2.5)$ are reported in this paper for all analyses.

Analytic Sample: A total of 23,258 participants ages 20 and older were selected to participate in NHANES III, 18, 825 were interviewed, and 16, 573 received the MEC examination including a blood draw. Excluded from that sample were those missing information on vital status ( $\mathrm{n}=11$ ), women who were pregnant at baseline ( $n=338$ ), who were missing data for serum total $25(O H) D(n=765)$, serum creatinine ( $n=344$ ), BMI ( $n=34$ ), and SBP ( $n=25$ ), and zero length of follow-up time from the date of examination ( $\mathrm{n}=7$ ) for a total analytic sample size of 15,099 participants. The analytic sample represents $80 \%$ of the interviewed sample, and $91 \%$ of the examined sample ages 20 years and older in NHANES III. In preliminary analyses it was found that while the NHANES III participants 20 years of age and older excluded from the analyses ( $\mathrm{n}=1,474$ ) compared with those included in the analytic sample ( $\mathrm{n}=15,099$ ) were slightly younger (mean age 40 yr . vs. 45 yr.), and included proportionally more women ( $64 \%$ vs. $51 \%$ ) and non-Hispanic blacks ( $20 \%$ vs. $10 \%$ ), they were remarkably similar in mean BMI (26.0 vs. 26.6), systolic blood pressure (119 vs. 123 mmHg ), the prevalence of current smokers ( $27 \%$ vs. $28 \%$ ), the percent examined during the months November-April (38\% vs. 38\%) and the prevalence with a self-
reported history of diabetes ( $5 \%$ vs. $5 \%$ ), congestive heart failure ( $2 \%$ vs. $2 \%$ ), stroke ( $2 \%$ vs. $2 \%$ ), heart attack (5\% vs. 4\%) and cancer (4\% vs. 4\%).

